Biogen has disclosed in a Wednesday Securities and Exchange Commission filing that it has been served a subpoena by the U.S. Department of Justice, which is seeking more information regarding the company’s overseas operations.
Tag Archive for: U.S. Securities and Exchange Commission (SEC)
An order from EU competition regulators for Illumina to sell cancer detection test maker Grail could come as early as next week, the Financial Times reported on Monday, citing people with knowledge of the matter.
AbbVie has ended its collaboration deal with Alector to develop one of two potential Alzheimer’s disease drugs. However, the relationship isn’t totally severed between the pair as they are still working to develop AL002, which is focused on targeting triggering receptors expressed on myeloid cells 2 (TREM2) also for Alzheimer’s Disease.
Biogen has terminated the company’s asset purchase agreement with Karyopharm Therapeutics, putting a halt to the development of KPT-350 (BIIB100), which was being tested in Phase I as a treatment for amyotrophic lateral sclerosis (ALS).
